XML 33 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholder’s deficit
9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Stockholder’s deficit

18. Stockholder’s deficit

 

  a) Common shares

 

Authorized and outstanding 

The Company has authorized 10,000,000,000 shares with a par value of $0.01 per share. The company has issued and outstanding 3,729,053,805 and 3,579,053,805 shares of common stock at September 30, 2022 and December 31, 2021, respectively.

 

On February 28, 2022, the Company issued 150,000,000 shares of common stock to Leonite in connection with a conversion notice received, converting principal of $149,250.

 

  b) Series A Preferred shares

 

Authorized, issued and outstanding 

The Company has authorized 10,000,000 Series A preferred shares with a par value of $0.01 per share. The company has issued and outstanding 4,000,000 Series A Preferred shares at September 30, 2022 and December 31, 2021, respectively.

 

  c) Series B Preferred shares

 

Authorized and outstanding 

The Company has authorized 400,000 Series B preferred shares with a par value of $1.00 per share. The company has issued and outstanding 400,000 Series B Preferred shares at September 30, 2022 and December 31, 2021, respectively.

 

The Series B preferred shares are mandatorily redeemable by the Company and are therefore classified as mezzanine debt.

 

  d) Stock options

 

Our board of directors adopted the Greenstone Healthcare Corporation 2013 Stock Option Plan (the “Plan”) to promote our long-term growth and profitability by (i) providing our key directors, officers and employees with incentives to improve stockholder value and contribute to our growth and financial success and (ii) enable us to attract, retain and reward the best available persons for positions of substantial responsibility. A total of 10,000,000 shares of our common stock have been reserved for issuance upon exercise of options granted pursuant to the Plan. The Plan allows us to grant options to our employees, officers and directors and those of our subsidiaries; provided that only our employees and those of our subsidiaries may receive incentive stock options under the Plan. We have no issued options at September 30, 2022 under the Plan.

 

  e) Warrants

 

All of the warrants have cashless exercise terms whereby in-the-money warrants may be exercised by reducing the number of shares issued in terms of the warrant exercise to offset the proceeds due on the exercise.

 

All of the warrants have price protection features whereby any securities issued subsequent to the date of the warrant issuance date, were issued at a lower price, or have conversion features that are lower than the current exercise price, or were converted at a lower price, or are exercisable at a lower price, to the current warrant exercise price, will result in the exercise price of the warrant being set to the lower issue, conversion or exercise price.

 

A summary of the Company’s warrant activity during the period from January 1, 2021 to September 30, 2022 is as follows:

    No. of shares   Exercise price
per share
  Weighted
average exercise
price
             
Outstanding as of January 1, 2021     615,561,379       $0.000675 to $0.12     0.011380  
Granted     471,010,103       $0.0020500       0.003080  
Forfeited/cancelled     (101,682,866 )     $0.0015 to $0.12       0.039029  
Exercised     (361,111,110 )     $0.00150 to $0.00205       0.003291  
Outstanding as of December 31, 2021     623,777,506       $0.000675 to $0.12     $ 0.0052875  
Granted              —         —    
Forfeited/cancelled     (20,925,000 )     $0.12       0.12  
Exercised              —         —    
Outstanding as of September 30, 2022     602,852,506       $0.000675 to $0.00205     $ 0.001306  

   

 

The following table summarizes information about warrants outstanding at September 30, 2022:

      Warrants outstanding     Warrants exercisable  
Exercise price     No. of shares    

Weighted average

remaining years

   

Weighted average

exercise price

    No. of shares    

Weighted average

exercise price

 
                                 
$0.000675       326,286,847       2.78               326,286,847          
$0.002050       276,565,659       3.27               276,565,659          
        602,852,506       3.01     $ 0.001306       602,852,506     $ 0.001306  

 

All of the warrants outstanding at September 30, 2022 are vested. The warrants outstanding at September 30, 2022 have an intrinsic value of $0.